HBM says partner Windward Bio starts Phase 3 asthma trial of twice-yearly TSLP antibody HBM9378/WIN378

PUBT · 1d ago
HBM says partner Windward Bio starts Phase 3 asthma trial of twice-yearly TSLP antibody HBM9378/WIN378
  • HBM Holdings highlighted positive interim Phase 2 asthma results for HBM9378/WIN378, an ultra-long-acting antibody targeting TSLP.
  • Patients showed sustained improvements in lung function and airway inflammation markers following a single dose, supporting a twice-yearly regimen.
  • Safety profile looked favorable, with no treatment-related serious adverse events reported in the interim dataset.
  • A Phase 3 study has started testing two twice-yearly doses; a second Phase 3 trial is planned for the first half of 2027.
  • Phase 2 results have not yet been presented at a congress; the release indicated they will be presented at a future medical meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42245) on September 08, 2026, and is solely responsible for the information contained therein.